BACKGROUND Glucocorticoids and L-asparaginase form essential components of induction therapy in Acute Lymphoblastic Leukaemia (ALL). These drugs produce hyperglycaemia in about 10-16% in children and 10-56% among adults. Hyperglycaemia has been associated with shorter duration of remission, decreased survival periods, increased infections and mortality rate. We wanted to study the prevalence of hyperglycaemia in patients suffering from ALL and the impact of hyperglycaemia during induction therapy. MATERIALS AND METHODS ALL patients admitted in the medicine ward and paediatric ward (Haematology) from July 2017-October 2018 were included in the study. Known cases of diabetes were excluded. Random blood glucose levels >200 mg/dL or fasting blood glucose >126 mg/dL in two occasions were defined as hyperglycaemia. All hyperglycaemic patients were treated with insulin (Basal and Sliding Scale). RESULTS The incidence of hyperglycaemia in the study was 23%. All of the hyperglycaemic patients were above 30 years of age. The prevalence of infections including bacterial and fungal infection was more in the hyperglycaemic group. The complete remission (CR) was achieved in 76.08% patients. There were 11 deaths during induction and 4 deaths after CR.